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a b s t r a c t
Many patients with type 2 diabetes continue to have poor glycaemic control and would
beneﬁt from insulin therapy. However, resistance to the introduction of insulin therapy can
be high on both the part of the healthcare provider and the patient. A number of new,
long-acting basal insulins are in development that provide good metabolic control, but with
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a lower risk of hypoglycaemia than currently available insulins, and greater ﬂexibility in
dosing time from day to day. These attributes may address some of the current barriers to
insulin initiation and intensiﬁcation that currently limit the effectiveness of diabetes care.
© 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd.
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Open access under CC BY-NC-ND license.. Introduction
he burden of type 2 diabetes is considerable, and people
ith diabetes require at least two- to three-times the health-
are resources of those who do not; therefore, diabetes care
ay account for up to 10–15% of national healthcare budg-
ts, rising to 17% by 2035 [1,2]. The progressive nature of
ype 2 diabetes means that insulin will ultimately be required
n many patients. The United Kingdom Prospective Diabetes
tudy (UKPDS) showed that 53% of patients with type 2 dia-
etes using only sulphonylurea required insulin therapy after
years, rising to ∼75% after 9 years [3,4]. Basal insulins can beused to augment oral therapy [5]. Moreover, the emergence of
odern basal insulins has led to the approach of basal–bolus
herapy in which basal insulins are administered alongside
∗ Corresponding author at: Department of Health Sciences, 22-28 Prince
el.: +44 116 252 5470.
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e
751-9918 © 2013 Primary Care Diabetes Europe. Published by Elsevier
ttp://dx.doi.org/10.1016/j.pcd.2013.09.003faster-acting prandial insulins – an approach to exogenous
insulin administration that more closely approaches physio-
logical insulin. Nevertheless, there are many insulin regimens
available, and it is difﬁcult to identify a consensus on the best
choice [6], highlighting the importance of discussion with the
atient and individualization of treatment.
Even though treatment goals and guidelines are well estab-
ished, many patients with type 2 diabetes continue to have
oor glycaemic control [7–9]. The beneﬁts of tight glycaemic
ontrol early in the course of disease are well established
10–12]; however, there remain clear barriers to uptake and
ffective use of insulin, for both physicians and patients.
From the physician’s perspective, many general practition-ss Road West, University of Leicester, Leicester LE1 6TP, UK.
rs perceive insulin therapy as a ‘last resort’ and 50–55% will
delay insulin therapy until they consider it absolutely neces-
sary [13]. Physicians cite a number of reasons for delaying
Ltd.  Open access under CC BY-NC-ND license.
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Fig. 1 – Chemical structure of insulin degludec, in which
the molecular structure of recombinant human insulin is
modiﬁed to allow the formation of soluble and stable
chains of hexameric insulin when injected into
subcutaneous tissue. Once in the subcutaneous depot, zinc
diffuses from the multi-hexamer assembly, releasing a
slow, peakless and continuous delivery of insulin
monomers into the circulation – a mechanism that has
been described in detail elsewhere [26]. With kind
permission from Springer Science+Business Media:
Pharmaceutical Research, Design of the novel protraction
mechanism of insulin degludec, an ultra-long-acting basal
insulin, 29, 2012, page 2105, Jonassen I et al., Fig. 1, ©2012.120 pr imary care d iab
insulin initiation; including beliefs around its efﬁcacy, con-
cerns around weight gain, occurrence of hypoglycaemia and
impaired quality of life or dissatisfaction for the patient [14].
This ‘clinical inertia’ – i.e. the failure to advance therapy when
it is required – is reﬂected in lowpercentages of patients inten-
sifying treatment when glycaemic control demands it. Indeed,
the recent global SOLVE observational study showed that the
mean glycosylated haemoglobin (HbA1c) of patients consid-
ered candidates for insulin initiation was 8.9%, although this
was subject to regional variation [15]. Prescribing a once-daily
long-acting insulin in combinationwith oralmedication is less
complicated than, for example, a twice-daily insulin regimen,
and will likely lead to a substantial increase in insulin therapy
in the primary care setting [16].
Similarly, barriers exist for patientswhowould beneﬁt from
insulin treatment. Complicated and inﬂexible insulin dosing
regimens can be intimidating to patients, and many have
concerns around weight gain, injection pain, fear of hypogly-
caemia and the perception that they will be viewed as sick,
or judged for having failed to manage their diabetes without
insulin [14,16–21]. The complexity of treatment, together with
the need to manage self-injection, can also adversely affect
patients’ quality of life [22].
Modern, long-acting basal insulin analogues, such as
insulin glargine and insulin detemir, are an improvement
on older preparations, as the glucose-lowering response in a
given patient is more consistent from one injection to another
[23,24]. However, clinical data show that the glucose-lowering
effect of current basal insulin analogues dosed once daily
can vary considerably over 24h [25]. These insulins are com-
monly dosed at bedtime or in the evening, reaching peak
plasma levels in the early hours or at breakfast time. The rising
kinetic proﬁle coupled with variability in absorption rate can
exacerbate the risk of nocturnal hypoglycaemia. This remains
a signiﬁcant barrier to insulin initiation and dose titration,
thereby limiting the achievement of optimum glycaemic con-
trol.
These issues highlight a requirement for improvements in
basal insulins, to better meet the needs of a growing pop-
ulation of patients with diabetes. This review considers the
clinical implications of emerging data for insulin degludec, a
new basal insulin, with a focus on type 2 diabetes.
2. Prolonging the action of basal insulins
Ideally, a basal insulin would need to deliver a constant and
predictable level of glucose-lowering effect over 24h from a
once-daily injection. Currently available basal analogues have
durations of action close to 24h. However, there may be little
or no overlap in the absorption (and hence glucose-lowering
action) between consecutive doses, so once-daily dosing can
result in a substantial difference between peak and minimum
plasma insulin levels, which may bring periods of exacer-
bated risk for hypo- andhyperglycaemia [24]. An insulinwith a
half-life substantially longer than 24h would allow once-daily
dosing and, on reaching steady state, would provide more sta-
ble plasma insulin levels than previously possible. With such
a proﬁle, some ﬂexibility in dose timing would also becomepossible, since day-to-day inconsistencies in administration
time would have only a minor impact on the plasma kinetics.
3. Insulin degludec
Insulin degludec (Fig. 1) is a new long-acting basal insulin with
a half-life of ≥25h [26] and a steady-state pharmacokinetic
(PK) proﬁle that is ﬂat and stable for >24h [27]. Isoglycaemic
clamp studies have shown that this stable PK proﬁle gives a
very stable glucose-lowering action that extends beyond 42h.
This leads to low variance in maximum and minimum plasma
insulin levels that can be achieved with once-daily dosing
[27].
The long and stable PK/pharmacodynamic (PD) proﬁle of
insulin degludec has a number of potential clinical impli-
cations, notably that the ﬂat and stable PK proﬁle, coupled
with low day-to-day variability should lead to good gly-
caemic control with a low incidence of hypoglycaemia. In
addition, the time at which once-daily injections are made
each day is less critical, promising greater tolerance for
ﬂexibility in dose timing. Both of these properties were
tested in the insulin degludec phase III clinical development
programme.
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. Clinical experience with insulin
egludec
nce-daily insulin degludec has been investigated in the
EGINclinical studyprogramme,withmore than5500patients
ecruited [28]. A treat-to-target protocol was used across the
linical programme, in which basal insulin doses were titrated
o the same self-measured fasting plasma glucose (FPG) level.
ifferences in treatments are therefore evident in other end-
oints, such as tolerability and safety; for example, the rate of
ypoglycaemia was an endpoint of primary interest.
.1. Glycaemic control
nboth type 1 and 2 diabetes, insulin degludec has been shown
o be non-inferior to insulin glargine in attaining and main-
aining glycaemic control [29–35]. In particular, in the BEGIN
B study, 992 patientswith type 2 diabeteswere randomized to
eceive either insulin degludec or insulin glargine for 52 weeks
29]. Both insulins were associated with similar levels of gly-
aemic control with change from baseline HbA1c of −1.1% in
hose receiving insulin degludec and−1.18% in those receiving
nsulin glargine. The estimated treatment difference of 0.08%
95% CI −0.05 to 0.21) conﬁrmed the non-inferiority of insulin
egludec to insulin glargine. FPG was reduced by 2.3mmol/L
ith insulin degludec and 2.0mmol/L with insulin glargine.
n HbA1c of <7.0% (<53mmol/mol) was achieved by 49% and
0% of patients, respectively.
The BEGIN ONCE LONG study randomized 1030 insulin-
aïve patients with type 2 diabetes to receive either insulin
egludec or insulin glargine, again over 52 weeks [30] Reduc-
ion in HbA1c with degludec was similar (non-inferior) to that
ith glargine (−1.06 vs. −1.19%), with an estimated treatment
ifference of degludec to glargine of 0.09% (95% CI 20.04–0.22).
PG was reduced by 3.76mmol/L with insulin degludec and
.31mmol/L with insulin glargine. Again, similar proportions
f patients achieved HbA1c levels of <7% at the end of the
rial with degludec (52%) and glargine (54%). These data are
upported by other studies from the insulin degludec clinical
tudy programme. (Table 1) [29–31].
.2. Hypoglycaemia
n patients with type 2 diabetes, numerical or statistically
igniﬁcant decreases were seen in the rates of both overall
onﬁrmed and nocturnal conﬁrmed hypoglycaemia com-
ared with insulin glargine. In these studies, conﬁrmed
ypoglycaemia was deﬁned as plasma glucose <3.1mmol/L
<56mg/dL), and nocturnal conﬁrmed hypoglycaemia as any
pisode occurring between midnight and 6:00 am. The BEGIN
B study showed that treatment with insulin degludec was
ssociated with a statistically signiﬁcant 18% reduction in risk
f conﬁrmed hypoglycaemia compared with insulin glargine
p=0.036) over 52 weeks, with rates of 11.1 and 13.6 episodes
er patient year of exposure, respectively [29]. A statistically
igniﬁcant reduction of 25% was also seen in the risk of noc-
urnal conﬁrmed hypoglycaemia (p=0.04) with rates of 1.39
ersus 1.84 episodes per patient year of exposure [29]. These
esults are supported by data from the ONCE LONG study
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[30] (Table 2). In this study, rates of overall conﬁrmed hypo-
glycaemia were similar between insulin degludec and insulin
glargine (1.52 vs. 1.85 events per patient year, respectively).
However, the rate of nocturnal conﬁrmed hypoglycaemia was
signiﬁcantly lower (by 36%; p=0.038) with insulin degludec,
with rates of 0.25 versus 0.39 episodes per patient year of
exposure, respectively. Few episodes of severe hypoglycaemia
were reported in either group, but the rate was signiﬁcantly
lower (p=0.017) with insulin degludec compared with insulin
glargine (0.003 vs. 0.023 episodes per patient year, respec-
tively). A recent meta-analysis showed that subjects with type
2 diabetes who were treated with insulin degludec experi-
enced signiﬁcantly lower rates of overall conﬁrmed (lower by
17%) and nocturnal conﬁrmed hypoglycaemic episodes (lower
by 32%) compared with insulin glargine (p<0.05). Results were
similar in insulin-experienced and insulin-naïve patients [36].
During exercise, increased glucose requirements as well
as increased insulin sensitivity can lead to an increased
risk of hypoglycaemia in patients with diabetes [37]. An
additional meta-analysis has indicated that the proportions
of patients self-reporting exercise-related hypoglycaemia,
both conﬁrmed and nocturnal, were similar between insulin
degludec and insulin glargine for all patient groups. Therefore
there was no increased risk of self-reported hypoglycaemia
related to exercise with insulin degludec compared with
insulin glargine [38].
4.3. Quality of life
It iswidely recognized that patientswith diabetes consistently
report lower health-related quality of life (HRQoL) compared
with those without [39,40]. Diabetes therapies can negatively
affect HRQoL due to treatment complexity/rigidity, fear of
hypoglycaemia and fear of injections [19,21,41,42]. Clinical
studies of insulin degludec have included assessments of
HRQoL, as measured using the SF-36 short-form health survey
[43]. Compared with insulin glargine, insulin degludec leads to
improvements in both mental and physical health status for
patients with type 2 diabetes [29].
In the BEGIN BB study, a HRQoL questionnaire showed a
statistically signiﬁcant difference between treatment groups
in favour of insulin degludec versus insulin glargine for the
SF-36 domain of bodily pain (estimated treatment difference
[ETD] 1.4 points [95% conﬁdence interval (CI) 0.1–2.7; p=0.032])
[29]. The ONCE LONG study showed an improvement in over-
all physical functioning at 52 weeks with insulin degludec
versus insulin glargine, with an ETD of 1 point [95% CI: 0.1–2.0]
(p=0.033) and a treatment difference of 1.4 points in the
physical functioning sub-domain [95% CI: 0.3–2.4] (p=0.016)
[30]. It should be noted, however, that statistical signiﬁcance
and clinical relevance may differ, and there has long been
some debate over what change in SF-36 score constitutes a
clinically relevant difference. This may only be meaningfully
assessed in a manner that takes into consideration speciﬁc
diseases, conditions, levels of severity, socioeconomic status,
and nationality of patients, as well as patients’ perceptions
[44].
Hypoglycaemia is known to have a substantial impact on
adherence to treatment, and particularly on HRQoL, through
acute symptoms, altered behaviour and fear of future events
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45,46]. Moreover, quality of life has been shown to decrease
irectly with increasing frequency of hypoglycaemic events
46]. Although the SF-36 measurement of HRQoL is not sufﬁ-
iently speciﬁc to identify true causal links, the improvements
nHRQoLevidentwith insulin degludec comparedwith insulin
larginemay be associatedwith the signiﬁcantly reduced inci-
ence of both overall and nocturnal hypoglycaemia.
. Addressing inﬂexibility in insulin dosing
egimens
any patients report that the restrictiveness of insulin regi-
ens is a signiﬁcant barrier to using insulin [21,41]. Indeed,
5% of patients reported restrictiveness as being a reason
o avoid insulin therapy [21]. Furthermore, patients report
rregular dosing of basal insulin; this may be due to busy
chedules, skipped meals and self-consciousness around hav-
ng to inject in a public place [42].
Up to 22% of patients plan daily activities around their
nsulin schedule [42]. Although a basal insulin requires dosing
nly once or twice daily, consistent dose timing is impor-
ant. This inﬂexibility may lead to patients not taking their
nsulin as prescribed, thereby limiting the achievement of
lycaemic targets. The ﬂat and stable steady-state proﬁle of
nsulin degludecmeans that consistency in the dosing interval
hould be less critical, and therefore allow for a more ﬂexible
osing interval, while still achieving glycaemic control with
ow hypoglycaemia [32].
This has been tested in an extreme scenario, in which
nsulin degludec given once daily in a ‘forced ﬂexible’ regi-
en incorporating alternating dosing intervals of 8 and 40h
etween doseswas comparedwith insulin glargine given once
aily at a ﬁxed time according to label. Meneghini and col-
eagues reported data for this regimen in patients with type
diabetes, which showed that changes in injection times
ould be made from day to day without compromising gly-
aemic control or increasing the incidence of hypoglycaemia
ompared with regular dosing of insulin glargine [32]. From a
aseline HbA1c of 8.4%, the ﬁxed and ﬂexible insulin degludec
egimens led to reductions of 1.1% and 1.3% points, respec-
ively, and a reduction of 1.3% points was seen with insulin
largine. Rates of conﬁrmed overall hypoglycaemia were 3.6
pisodes per patient year in the insulin degludec groups
nd 3.5 episodes per patient year in the insulin glargine
roup; rates of conﬁrmed nocturnal hypoglycaemia were 0.6
pisodes per patient year in the insulin degludec groups
nd 0.8 episodes per patient year in the insulin glargine
roup.
While it is unwise to encourage laxity in self-management,
he greater dosing ﬂexibility afforded by insulin degludec may
epresent a major improvement in patient convenience by
llowing injection times to be changed daily according to indi-
idual needs.. Next steps for insulin degludec
nsulin degludec is approved for use in Europe, Japan,
exico and Switzerland. Additionally, in November 2012, the( 2 0 1 4 ) 119–125 123
Endocrinologic and Metabolic Drugs Advisory Committee to
the United States Food and Drug Administration (FDA) voted
in favour of approval for insulin degludec in the United States.
However, in February 2013, the FDA requested additional clini-
cal data from a dedicated cardiovascular outcomes trial before
the review of the New Drug Application can be completed.
As the focus of the insulin degludec phase 3 trials was on
glycaemic efﬁcacy and the relationship between glycaemic
efﬁcacy and the risk of hypoglycaemia, this additional study
will add to the body of data available to inform the clinical use
of insulin degludec.
7. Conclusions
Basal insulins form the cornerstone of many treatment
regimens for patients with type 2 diabetes. The need for
improvements in basal insulin has led to the development of
new candidate insulins with more favourable characteristics.
Insulindegludec is anew long-actingbasal insulin that confers
slow absorption and a ﬂat and stable glucose-lowering action
extending beyond 42h.
This insulin provides a new approach that may help
to address some of the concerns around initiating insulin
therapy. The most signiﬁcant clinical impact is a reduction
in nocturnal hypoglycaemia. These ﬁndings are important
because differences in nocturnal risk cast more light on
the true differences between basal insulins than hypogly-
caemia during the daytime, which is also inﬂuenced by
factors such as prandial insulin, food intake and exercise.
The prospect of a basal insulin with a very low noc-
turnal hypoglycaemia risk may be helpful in addressing
both clinicians’ and patients’ fears around hypoglycaemia
as well as in reducing hypoglycaemia-associated healthcare
costs.
The ability to exercise greater ﬂexibility in dosing sched-
ules may help to lessen the effects of irregular insulin dosing
and be of beneﬁt to patients who ﬁnd it difﬁcult to adhere
to a strict dosing schedule or who are reluctant to inten-
sify to insulin treatment because of perceptions around the
restrictions or intrusiveness of the regimen. Again, this may
be of beneﬁt in better optimizing glycaemic control for these
patients.
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Summary points
Many patients with type 2 diabetes continue to have poor
glycaemic control and would beneﬁt from insulin ther-
apy.
Resistance to the introduction of insulin therapy can be
high on both the part of the healthcare provider and the
patient.
Insulin degludec is a new generation basal insulin which
undergoes slow absorption from the subcutaneous depot
resulting in a long duration of action, a ﬂat and stable
PK/PD proﬁle and lower day-to-day variability providing
effective glycaemic control.
Insulin degludec may be given at any time of day (prefer-
ably at the same timeevery day), and administration time
can vary from day to day without compromising efﬁcacy
or safety (a minimum of 8h between injections should
always be ensured).
In a recent meta-analysis, patients with type 2 diabetes
treated with insulin degludec showed signiﬁcantly lower
rates of overall conﬁrmed hypoglycaemia (lower by up to
17%) and nocturnal conﬁrmed hypoglycaemia (lower by
32%) compared with insulin glargine.
A reduction in hypoglycaemia can improve patient qual-
r
long-acting insulins. An assessment of the basal analoguesity of life.
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